Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01822509 | Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant | completed | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 1 | Jun 24, 2021 | clinicaltrials |
| NCT02424968 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 18 | Robert LowskyOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT00860574 | Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | completed | Phase 2 | 96 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT01817075 | Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant | completed | Phase 3 | 177 | Children's Oncology GroupNETWORK | 3 | Jun 22, 2021 | clinicaltrials |
| NCT01787474 | Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT00378534 | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | completed | Phase 2 | 116 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT01926587 | Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine | completed | Phase 1 / Phase 2 | 45 | Traws Pharma, Inc.INDUSTRY | 2 | Jun 16, 2021 | clinicaltrials |
| NCT00988013 | Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies(IM-TMI) | completed | N/A | 14 | University of Illinois at ChicagoOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT01768845 | Unrelated Umbilical Cord Blood (UBC)Transplantation | completed | N/A | 34 | West Virginia UniversityOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT01861002 | A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | completed | Phase 1 | 15 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 3 | Jun 9, 2021 | clinicaltrials |
| NCT04910698 | Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia | completed | — | 104 | Poitiers University HospitalOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT02190695 | Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS | completed | Phase 2 | 92 | Fox Chase Cancer CenterOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02485535 | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | completed | Phase 1 | 12 | University of ChicagoOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT02129582 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 1 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2(DEPLETHINK) | completed | Phase 1 / Phase 2 | 21 | Celyad Oncology SAINDUSTRY | 2 | May 4, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT02809222 | Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls(PLASMYC) | completed | N/A | 138 | University Hospital, ToursOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT01361334 | Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible(PAZOPANIB-AML) | completed | Phase 2 | 20 | University Hospital MuensterOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01307579 | Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia | completed | Phase 3 | 517 | Children's Oncology GroupNETWORK | 3 | Mar 30, 2021 | clinicaltrials |
| NCT03790072 | Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML) | completed | Phase 1 | 10 | TC BiopharmINDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01961882 | A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia | completed | Phase 2 | 134 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 3 | Mar 26, 2021 | clinicaltrials |
| NCT00606723 | Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML | completed | Phase 3 | 154 | Hannover Medical SchoolOTHER | 3 | Mar 22, 2021 | clinicaltrials |
| NCT01338987 | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | completed | Phase 2 | 76 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2021 | clinicaltrials |
| NCT01883362 | Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML(RADIUS) | completed | Phase 2 | 60 | Novartis PharmaceuticalsINDUSTRY | 2 | Mar 17, 2021 | clinicaltrials |
| NCT03081780 | Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | completed | Phase 1 | 6 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 12, 2021 | clinicaltrials |
| NCT01288222 | Selecting a Favorable KIR Donor in Unrelated HCT for AML | completed | N/A | 506 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT01440920 | A Phase I Study of OCV-501 in Acute Myeloid Leukemia Patients | completed | Phase 1 | 9 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 8, 2021 | clinicaltrials |
| NCT01807091 | Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | completed | N/A | 17 | University of WashingtonOTHER | 1 | Mar 5, 2021 | clinicaltrials |
| NCT02293993 | Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia | completed | Phase 1 | 21 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 5, 2021 | clinicaltrials |
| NCT01475370 | Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001) | completed | Phase 1 | 18 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 2, 2021 | clinicaltrials |
| NCT01736943 | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | completed | Phase 2 | 25 | Joseph TuscanoOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT02039726 | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | completed | Phase 3 | 367 | Daiichi SankyoINDUSTRY | 19 | Feb 24, 2021 | clinicaltrials |
| NCT01025778 | Haploidentical Stem Cell Transplantation for Children With Therapy Resistant Leukemia | completed | Phase 2 | 7 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03197714 | Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia | completed | Phase 1 | 9 | Hospital Universitario 12 de OctubreOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT01912274 | Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 2 | 50 | Helsinn Healthcare SAINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT00637052 | A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT01445080 | Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Feb 2, 2021 | clinicaltrials |
| NCT00469014 | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 26, 2021 | clinicaltrials |
| NCT01713582 | A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | completed | Phase 1 | 141 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT00469144 | IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome | completed | Phase 3 | 233 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 19, 2021 | clinicaltrials |
| NCT03488862 | Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients | completed | — | 34 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT01180322 | Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine(azacitidine) | completed | Phase 2 | 277 | University of UlmOTHER | 2 | Dec 31, 2020 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00831766 | Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 51 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00093600 | PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 1 | 69 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01055483 | A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia | completed | Phase 1 | 59 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 24, 2021source: clinicaltrials